№ lp_2_1_08028
File format: docx
Character count: 3507
File size: 68 KB
UC-MSCs are mesenchymal stem cells derived from umbilical cord tissue, known for their high vitality, differentiation potential, and immunomodulatory properties, used in regenerative medicine and neurological treatments.
Year:
Not specified
Region / City:
Not specified
Topic:
Stem Cells, Regenerative Medicine
Document Type:
Product Description
Organization / Institution:
Not specified
Author:
Not specified
Target Audience:
Researchers, Medical Professionals
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2023
Region / City:
Japan
Topic:
Pulmonary disease, stem cells, regenerative medicine
Document Type:
Research article
Organization / Institution:
Nagasaki University, Tokyo University
Author:
Mayumi Iwatake, Tokiko Nagamura-Inoue, Ryoichiro Doi, Yukinori Tanoue, Mitsutoshi Ishii, Hiroshi Yukawa, Tomoshi Tsuchiya
Target Audience:
Researchers, clinicians in regenerative medicine
Period of Validity:
N/A
Approval Date:
N/A
Date of Changes:
N/A
Cell culture:
Human umbilical cord mesenchymal stem cells (UC-MSCs)
Animal model:
C57BL/6 mice
Ethical compliance:
Nagasaki University Institutional Animal Care and Use Committee
Note:
Approval No. 1807101460-2
Author:
Nik Heijmink
Student number:
6706541
Date:
12/08/2024
Type of document:
Writing assignment
Academic program:
Neuroscience and Cognition master program, Experimental and Clinical Neuroscience track
Institution:
University Medical Centre Utrecht
Department:
Department for Developmental Origins of Disease, Division Woman and Baby, Brain Center
City:
Utrecht
Country:
The Netherlands
Daily supervision:
M.J.V. Brandt, PhD
Examiner:
C.H.A. Nijboer, Associate Professor
Secondary examiner:
R.J. Pasterkamp, Full Professor
Main topic:
Hypoxic-ischemic encephalopathy and mesenchymal stem cell-derived extracellular vesicles
Key subjects:
Neuroinflammation, neurogenesis, hypothermia treatment, microglia, subventricular zone, exosomes
Authors:
Cassandra M. Juran; Justina Zvirblyte; Yasaman Sharazi; Angela Kubik; Margareth Cheng-Campbell; Elizabeth Blaber; Eduardo Almeida
Affiliations:
Blue Marble Space Institute of Science at NASA Ames Research Center, Mountain View, CA, USA; Vilnius University, Vilnius, Lithuania; Rensselaer Polytechnic Institute, Troy, NY, USA; NASA Ames Research Center, Moffett Field, CA, USA
Research Field:
Stem cell biology; Bone regeneration; Mechanobiology; Space biology
Key Gene:
CDKN1A (Cdkn1a)
Experimental Models:
Wildtype and Cdkn1a-null mice
Methods:
Single-cell mRNA sequencing; in-vitro mechanical stretch; hindlimb unloading; running wheel and treadmill loading; spaceflight microgravity exposure
Space Mission:
Rodent Research-10 aboard the International Space Station
Duration of Spaceflight:
30 days
Biological Material:
Femur bone marrow; mesenchymal osteoprogenitors; osteoblast lineage cells
Type of Document:
Scientific research article
Institutional Context:
NASA-affiliated and academic biomedical research collaboration
Effective Date:
August 26, 2025
Product Name:
Adipose Mesenchymal Stem Cell Exosomes (ADSC-Exos)
Manufacturer:
YI MIN BIOLOGICAL MEDICINE
Contact Phone:
+86 18506213676
Company Address:
Building 1, Gangtian Industrial Park, No. 99 Gangtian Road, Industrial Park, Suzhou, Jiangsu Province, China
Product Type:
Raw material ingredient
Product Form:
Liquid form; Lyophilized powder form
Core Active Ingredient:
Exosomes secreted by adipose mesenchymal stem cells (≥1×10¹⁰ particles/mL)
Excipients:
Serum-free culture medium; Glycerol (5%-10%)
Non-Containing Components:
No antibiotics; No preservatives; No additional animal-derived materials; No heavy metals (<0.1 ppm)
Exosome Diameter:
30–150 nm (average 80–100 nm)
Marker Proteins:
CD9, CD63, CD81, CD29, CD44, CD73
Sterility:
No bacterial or fungal growth
Endotoxin Content:
<0.5 EU/mL
pH Value (Liquid Form):
6.5–7.5
Purity:
≥90%
Storage Conditions:
2–8°C or -20°C depending on form
Shelf Life:
6–24 months depending on form and temperature
Transportation Requirements:
Professional cold chain; ≤72 hours
Scope of Application:
Scientific research experiments; Cosmetics; Medical devices
Usage Restrictions:
Not for direct injection, oral administration, or direct use as drug or health supplement
Liability Statement:
Manufacturer responsible only under specified storage, transportation, and usage conditions
After-Sales Contact Email:
[email protected]
Revision Policy:
Subject to updates due to technology or regulatory changes
Year:
2026
Region / city:
Global
Subject:
Cell therapy, regenerative medicine
Document type:
Product description
Organization:
[Manufacturer / Supplier Name]
Author:
[Author / Researcher Name, if mentioned]
Target audience:
Researchers, healthcare professionals
Validity period:
Not specified
Approval date:
Not specified
Modification date:
Not specified
Year:
2021
Region / city:
Tianjin, China
Subject:
Stem Cell Therapy, Neurological Function, Ischemic Stroke, Gut Microbiota
Document type:
Research Article
Organization / Institution:
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin Key Laboratory of Translational Research of TCM Prescription and Syndrome
Author:
Zhao LN, Ma SW, Xiao J, Yang LJ, Xu SX, Zhao L
Target audience:
Researchers, Healthcare professionals, Medical practitioners
Period of validity:
Not specified
Approval date:
December 11, 2021
Date of revisions:
July 6, 2021
Publication date:
December 26, 2021
Year:
2021
Region / city:
Not specified
Topic:
Mesenchymal cells in bone marrow of AML patients
Document type:
Research Supplementary Data
Organization / institution:
Not specified
Author:
Not specified
Target audience:
Researchers, medical professionals
Effective period:
Not specified
Date of approval:
Not specified
Date of changes:
Not specified
Year:
2026
Region / City:
Not specified
Topic:
Bone Regeneration, Macrophage Phenotype Switching
Document Type:
Research Article
Organization / Institution:
Not specified
Author:
Not specified
Target Audience:
Researchers, Medical Professionals
Duration:
Not specified
Approval Date:
Not specified
Modification Date:
Not specified
Year:
2010–2025
Region / City:
Italy
Topic:
Molecular profiling of mesenchymal tumors
Document type:
Consensus paper supplement
Institution:
Italian Sarcoma Group
Audience:
Medical researchers, oncologists, pathologists
Methods:
Literature review, PubMed search, article screening
Number of articles reviewed:
2,699
Number of articles included in final analysis:
146
Additional publications considered:
December 31, 2024 – August 31, 2025
Filters applied:
Full text, clinical trials, guidelines, meta-analyses, observational studies, humans, English language
Search strategy:
Next-generation sequencing, genomic profiling, liquid biopsy, RNAseq, fusion panel, methylation
Reference list selection:
Most relevant articles according to journal guidelines
Systematic review type:
Consensus-based literature review
Screening process:
Title screening, abstract evaluation, full-text evaluation